New drug cocktails aim to shrink tumors before cancer surgery
NCT ID NCT04080804
Summary
This study tests whether giving one or two immunotherapy drugs before surgery is safe and can help shrink tumors in people with operable head and neck cancer. About 80 patients will receive either nivolumab alone or combined with another drug (relatlimab or ipilimumab) for a few weeks prior to their planned operation. The main goals are to check for serious side effects and see how much the tumors respond to treatment before removal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.